Biostem Technologies Inc. (BSEM)
OTC PINK OTC PINK Primary 
BioStem Announces Notice of Allowance for U.S. Patent Application for Sterile Human Placental Allografts
Company continues to advance its placental-derived product portfolio with the first patent granted in the fenestrated wound care market POMPANO BEACH, Fla., Nov. 25, 2024 – PRISM MediaWire – BioStem Technologies, Inc.
BioStem Technologies Signs Letter of Intent to Acquire Wound Care Products and Technologies from ProgenaCare Global
Additions of ProgenaMatrix®and revyve™ Antimicrobial Wound Gel part of planned expansion of BioStem's commercial product portfolio POMPANO BEACH, Fla., November 20, 2024 – PRISM MediaWire – BioStem Technologies Inc.
Long-Term, BioStem Technologies Still A Promising Growth Stock
BioStem Technologies has experienced significant price volatility, driven by positive news and uplisting plans, but recent profit-taking has caused a pullback. Q3 earnings report showed impressive growth with record revenue and positive net income, reinforcing the company's strong financial performance. Future growth looks promising with a robust product pipeline and potential Nasdaq uplisting, supporting a one-year price target of $27.88.
BioStem Technologies, Inc. (BSEM) Q3 2024 Earnings Call Transcript
BioStem Technologies, Inc. (OTCPK:BSEM) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Adam Holdsworth - Investor Relations Jason Matuszewski - Chief Executive Officer Michael Fortunato - Chief Financial Officer Conference Call Participants Ernest Watts - Watts Associates Operator Thank you for standing by. My name is Rebecca and I will be your conference operator today.
BioStem Technologies Reports Record Third Quarter 2024 Revenue of $82.6 Million
POMPANO BEACH, FL, November 12, 2024 – PRISM MediaWire – BioStem Technologies, Inc. (OTC: BSEM) (the “Company” or “BioStem”), a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived biologics, today reported financial results for the third quarter ended September 30, 2024.
BioStem Technologies to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
Conference Call and Webcast to be held at 4:30 PM ET POMPANO BEACH, Fla., October 28, 2024 – PRISM MediaWire – BioStem Technologies Inc.
BioStem Technologies Reports Breakthrough Results in a Diabetic Foot Ulcer Wound Closure Study Comparing BioREtain® to Standard of Care Treatment
Retrospective Study demonstrates clinical efficacy and statistical support for tissue processed via BioREtain to care for treatment-resistant chronic wounds Study published in the peer-reviewed journal, ‘International Wound Journal' POMPANO BEACH, Fla., Oct. 17, 2024 – PRISM MediaWire – BioStem Technologies, Inc.
BioStem Technologies Establishes National Pricing for Vendaje AC® from the Center for Medicare Services and Provides Reimbursement in All MAC Regions
Vendaje AC to launch across MAC regions nationwide through Venture Medical, the Company's exclusive sales and marketing partner for AmnioWrap2® POMPANO BEACH, Fla., Oct. 15, 2024 – PRISM MediaWire – BioStem Technologies, Inc.
BioStem Technologies Initiates BR-AC-DFU-101 Clinical Trial to Study BioREtain® in Diabetic Foot Ulcers
Strategic head-to-head study of BR-AC vs. standard of care aims to demonstrate healing superiority potential to support increased payor coverage and market growth The study will be conducted in 60 patients at 10 sites across the U.S. and the first patients have begun treatment POMPANO BEACH, Florida, October 2, 2024 – BioStem Technologies, Inc.
BioStem Technologies, Inc. Files Form 10 with the Securities and Exchange Commission and Submits Nasdaq Application for Uplisting
Nasdaq listing aims to increase market visibility and global liquidity opportunities as BioStem advances its commercial and clinical initiatives amid record revenue growth Pompano Beach, FL, September 30, 2024 – PRISM MediaWire – BioStem Technologies, Inc.
BioStem Technologies Inc. to Present at the H.C. Wainwright 26th Annual Global Investment Conference in New York on September 9th at 3:30 PM ET
Advanced wound care MedTech company recently reported a record second-quarter with $116.4M in revenue for H1, 2024 POMPANO BEACH, Fla., Aug. 29, 2024 — BioStem Technologies Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care, will present at the H.C.
BioStem Receives Institutional Review Board (IRB) Approval to Advance Clinical Study Evaluating the Value of Vendaje® Compared to the Standard of Care for Non-Healing Diabetic Foot Ulcers
Study supports BioStem's strategic growth initiatives and accelerates product adoption by providing data to healthcare professionals and payers on the benefits of Vendaje POMPANO BEACH, FL, August 21, 2024 – BioStem Technologies Inc.
